Parexel talks global trial regulations at DIA 2011

By Gareth Macdonald

- Last updated on GMT

US CRO Parexel says the pharmaceutical industry’s desire to access international markets is the key challenge facing regulatory experts in the contract research sector.

Alberto Grignolo, VP of global strategy and services told that “twenty years ago the name of the game was running clinical trials in the US and Europe…nowadays companies begin drug development with the world in mind.”

Dr Grignolo explained that this means developers must interact with a greater number of regulatory bodies worldwide, which in turn is driving demand for contract research organisations (CRO) that can assist in this process.

“This creates opportunities to be creative,” he continued “clients want to take medicines to the world and they are looking for partners, such as Parexel, that can help them do this.​”

Related news

Show more

Related products


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers